Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.1016/j.annonc.2020.08.456
Twittear
| Título: | Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study |
| Fecha de publicación: | sep-2020 |
| Editorial: | Elsevier |
| Cita bibliográfica: | Annals of Oncology, 2020, Vol. 31, Issued S4, pp. S391 |
| ISSN: | Print: 0923-7534 Electronic: 1569-8041 |
| Resumen: | T-DM1 is the standard second-line treatment for HER2-positive Metastatic Breast Cancer (HER2+ MBC) patients. In clinical practice, it is not possible to predict which patients will benefit the most from T-DM1. Furthermore, the mechanisms of primary and acquired resistance to T-DM1 remain largely uncharacterized. The task of uncovering such mechanisms in a clinical setting is challenging and requires a comprehensive approach. |
| Autor/es principal/es: | Rojo Todo, F. Stradella, A. García Sáenz, J. A. Bermejo de las Heras, B. Alonso Romero, José Luis Barnadas, A. Izarzugaza Peron, Y. Alba, E. López Tarruella, S. Henao Carrasco, F. Carrasco, E. Caballero, R. Del Campo, M. |
| Versión del editor: | https://www.sciencedirect.com/science/article/pii/S0923753420404521?via%3Dihub |
| URI: | http://hdl.handle.net/10201/146001 |
| DOI: | https://doi.org/10.1016/j.annonc.2020.08.456 |
| Tipo de documento: | info:eu-repo/semantics/article |
| Número páginas / Extensión: | 1 |
| Derechos: | info:eu-repo/semantics/embargoedAccess |
| Descripción: | © 2020 European Society for Medical Oncology. This document is the Published version of a Published Work that appeared in final form in Annals of Oncology. To access the final edited and published work see https://doi.org/10.1016/j.annonc.2020.08.456 |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| PIIS0923753420404521.pdf | 85,62 kB | Adobe PDF |  Visualizar/Abrir Solicitar una copia |
Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.